Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced the publication of a new study in npj Precision Oncology highlighting the power of its ...
A single fecal microbiota transplantation from healthy donors increases the efficacy of immune checkpoint inhibition in both NSCLC and melanoma.
Early results from the ongoing QUILT-106 clinical trial (NCT06334991) show that the treatment combination of CD19 chimeric antigen receptor natural killer (CAR-NK) cells with rituximab (Rituxan) can ...
ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced the launch of ResQ215B, a Phase 2 ...
Patient Glioblastoma Response to CAR-T Cell Therapy Mirrored in Tumor-Derived Organoids in Real Time
Researchers at the Perelman School of Medicine at the University of Pennsylvania have for the first time used lab-grown organoids created from tumors of individuals with glioblastoma (GBM) to ...
Dr Sattva S. Neelapu discusses data from the ZUMA-5 trial investigating the CAR T-cell therapy Yescarta in relapsed/refractory follicular lymphoma. Treatment with the CAR T-cell therapy Yescarta ...
Treatment with cemacabtagene ansegedleucel demonstrated responses in patients with relapsed or treatment-resistant large B-cell lymphoma. Treatment with cemacabtagene ansegedleucel (cema-cel) ...
Older women could be vulnerable to harmful inflammation from new gene therapies to treat incurable eye diseases, new research has found. The University of Bristol-led study, published in Molecular ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results